The Journal of Hepatocellular Carcinoma is a pivotal open-access publication dedicated to advancing the field of hepatocellular carcinoma research. Published by DOVE MEDICAL PRESS LTD since 2014, this journal seeks to disseminate high-quality articles that explore innovative treatments, clinical trials, and emerging research in the context of liver cancer. With its ISSN: N/A and E-ISSN: 2253-5969, the journal is optimized for a global audience, ensuring accessibility to a broad spectrum of researchers, healthcare professionals, and students engaged in oncology and hepatology. While its Scopus ranking places it in the lower quartiles of the respective fields, the journal continues to strive for growth and visibility in a rapidly evolving landscape. The Journal of Hepatocellular Carcinoma is an essential resource for anyone seeking to enhance their understanding of liver diseases and contribute to the fight against hepatocellular carcinoma.

Liver Cancer is a premier, peer-reviewed journal dedicated to the comprehensive study and advancement of knowledge surrounding liver neoplasms. Published by KARGER and headquartered in Switzerland, this journal has been an open-access platform since 2012, providing researchers with invaluable insights into the rapidly evolving field of hepatology and oncology. With an impressive impact factor that places it in the Q1 category for both Hepatology and Oncology in 2023, Liver Cancer stands out as a high-impact conduit for groundbreaking research, ranking #19 out of 404 in Medicine _ Oncology and #6 out of 82 in Medicine _ Hepatology according to Scopus. Researchers, practitioners, and students are encouraged to engage with the journal's content, which encompasses clinical studies, basic research, and reviews that contribute significantly to understanding liver cancer dynamics, diagnosis, and treatment strategies. This journal not only facilitates the dissemination of knowledge but also fosters collaboration in a well-established and impactful global scientific community.

World Journal of Hepatology is a premier academic journal dedicated to advancing the field of hepatology. Published by BAISHIDENG PUBLISHING GROUP INC, this journal serves as a crucial platform for disseminating innovative research findings and critical reviews from around the globe. With its ISSN 1948-5182 and E-ISSN 1948-5182, the journal has established a notable presence since its inception in 2009, covering a wide range of topics relevant to liver diseases, including but not limited to hepatitis, liver cancer, and metabolic liver disorders. Currently ranked 41/82 in the field of hepatology by Scopus, representing the 50th percentile, it has achieved a Q3 quartile ranking in the 2023 category, underscoring its growing influence in the medical community. With a commitment to open access for its readership, the World Journal of Hepatology enriches the global discourse on liver health and disease management, making it an essential resource for researchers, clinicians, and students alike.

CANCER JOURNAL is a leading peer-reviewed publication dedicated to the dissemination of innovative research in the fields of cancer research and oncology. Published by Lippincott Williams & Wilkins, this journal serves as an essential resource for researchers, clinicians, and students seeking to advance their understanding of cancer mechanisms, treatment strategies, and patient care. With an ISSN of 1528-9117 and an E-ISSN of 1540-336X, it boasts a respectable 2023 Q2 category ranking in both Cancer Research and Oncology, reflecting its impactful contributions to the scientific community. Although it currently does not offer open access, the journal's rigorous peer-review process ensures the publication of high-quality, relevant studies that stimulate further investigation and collaboration among professionals. Since its inception, the journal has evolved through several converged years, maintaining a steadfast commitment to addressing the complexities of cancer biology and treatment. At its core, CANCER JOURNAL aims to foster advancements in oncology, making it a vital platform for sharing pivotal findings that could transform cancer research and therapeutic practices.

Hepatology Communications, published by Lippincott Williams & Wilkins, serves as a pioneering platform in the field of hepatology, dedicated to advancing the understanding of liver diseases and treatments. Since its inception in 2017, this open access journal has rapidly gained recognition, achieving an impressive Q1 ranking in Hepatology as of 2023, and appealing to a diverse audience of researchers, clinicians, and students alike. With its focus on high-quality research and clinical studies, the journal aims to facilitate impactful discussions and disseminate vital findings that address the challenges faced in liver health. Operating out of the United States, and accessible globally, Hepatology Communications is committed to fostering a collaborative research environment and enhancing the visibility of scholarly work in hepatology, ultimately driving forward innovations in patient care and treatment strategies.

Hepatology International is a premier academic journal dedicated to advancing the field of liver research and hepatology. Published by SPRINGER, this journal boasts a prestigious Q1 ranking in Hepatology as of 2023, underscoring its commitment to high-quality research dissemination. The journal’s scope encompasses a wide range of topics related to liver disease, including clinical, translational, and basic science studies. With its impact factor reflecting its relevance and influence in the field, Hepatology International serves as an essential resource for researchers, clinicians, and students aiming to keep abreast of the latest developments and breakthroughs. Though traditionally a subscription-based journal, it offers a vast array of insightful articles that contribute significantly to our understanding of hepatological conditions. The journal continues its trajectory of growth since its inception in 2008, anticipating a convergence of knowledge and innovation through to 2024. Located in the heart of New York City, this journal not only represents a crucial platform for global hepatology research but also fosters a collaborative community of experts dedicated to improving liver health worldwide.

Therapeutic Advances in Gastroenterology, published by SAGE Publications Ltd, is a premier open access journal dedicated to the advancement of knowledge in the field of gastroenterology. Since its inception in 2008 and its transition to open access in 2018, the journal has consistently provided high-quality peer-reviewed research articles, review papers, and clinical studies that address the latest therapeutic advancements and challenges in gastrointestinal medicine. With an impressive impact factor and a 2023 Scopus ranking placing it in the Q1 quartile of gastroenterology journals, it stands as a leading platform for researchers, clinicians, and healthcare professionals. The journal’s commitment to disseminating impactful research has positioned it at the forefront of academic discourse, offering a vital resource for those devoted to improving patient outcomes in digestive health. The United Kingdom-based journal invites submissions that contribute to the understanding and treatment of gastrointestinal disorders, ensuring that cutting-edge findings reach a global audience.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.

Hepatoma Research is a pivotal academic journal dedicated to advancing the field of hepatology and oncology, published by OAE PUBLISHING INC. Launched in 2019, this open-access journal has quickly established itself as a valuable resource for researchers and professionals dedicated to the study of liver cancer and related disorders. With an ISSN of 2394-5079 and E-ISSN 2454-2520, it offers insightful research articles and reviews aimed at enhancing clinical practices and understanding the complexities surrounding hepatoma. The journal is ranked in the Q3 category for both hepatology and oncology as of 2023, reflecting its commitment to quality amidst a competitive landscape. With its Scopus rankings placing it at the 47th percentile in hepatology and the 39th percentile in oncology, Hepatoma Research continues to be a crucial platform for disseminating groundbreaking findings. This journal underscores the importance of collaborative research and encourages submissions that contribute to the global discourse on liver cancer treatment and management.